Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uros Markovic

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|October 9, 2023
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experienceAndrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, et al.
Cancers|March 10, 2022
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 InfectionAlessandra Romano, Claudio Cerchione, Concetta Conticello, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 7, 2025
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real-Life Case Series and Literature ReviewGaetano Giuffrida, Uros Markovic, Stephanie Grasso, et al.
Frontiers in Oncology|December 4, 2025
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologistsMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Journal of Clinical Medicine|October 19, 2019
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsMarina Silvia Parisi, Salvatore Leotta, Alessandra Romano, et al.
Leukemia Research Reports|November 18, 2020
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable costGiuseppe Milone, Concetta Conticello, Salvatore Leotta, et al.
Frontiers in Immunology|March 3, 2020
Preliminary Results of a Combined Score Based on sIL2-Rα and TIM-3 Levels Assayed Early After Hematopoietic TransplantationSalvatore Leotta, Giuseppe Sapienza, Maria Grazia Camuglia, et al.
Chemotherapy|September 19, 2019
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of ChemotherapySalvatore Leotta, Maria Cristina Pirosa, Uros Markovic, et al.
Frontiers in Pharmacology|June 1, 2026
The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort studyUros Markovic, Gabriele Sapuppo, Sara Frazzetto, et al.
International Journal of Molecular Sciences|June 23, 2020
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3Fabrizio Puglisi, Nunziatina Laura Parrinello, Cesarina Giallongo, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|October 9, 2023
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experienceAndrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, et al.
Cancers|March 10, 2022
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 InfectionAlessandra Romano, Claudio Cerchione, Concetta Conticello, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 7, 2025
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real-Life Case Series and Literature ReviewGaetano Giuffrida, Uros Markovic, Stephanie Grasso, et al.
Frontiers in Oncology|December 4, 2025
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologistsMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Journal of Clinical Medicine|October 19, 2019
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsMarina Silvia Parisi, Salvatore Leotta, Alessandra Romano, et al.
Leukemia Research Reports|November 18, 2020
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable costGiuseppe Milone, Concetta Conticello, Salvatore Leotta, et al.
Frontiers in Immunology|March 3, 2020
Preliminary Results of a Combined Score Based on sIL2-Rα and TIM-3 Levels Assayed Early After Hematopoietic TransplantationSalvatore Leotta, Giuseppe Sapienza, Maria Grazia Camuglia, et al.
Chemotherapy|September 19, 2019
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of ChemotherapySalvatore Leotta, Maria Cristina Pirosa, Uros Markovic, et al.
Frontiers in Pharmacology|June 1, 2026
The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort studyUros Markovic, Gabriele Sapuppo, Sara Frazzetto, et al.
International Journal of Molecular Sciences|June 23, 2020
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3Fabrizio Puglisi, Nunziatina Laura Parrinello, Cesarina Giallongo, et al.
Pageof 5